Identification
- Summary
Oritavancin is an antibacterial agent used to treat acute bacterial skin and skin structure infections caused by susceptible Gram-positive bacteria.
- Brand Names
- Kimyrsa, Orbactiv
- Generic Name
- Oritavancin
- DrugBank Accession Number
- DB04911
- Background
Oritavancin is a glycopeptide antibiotic used for the treatment of skin infections. It was developed by The Medicines Company (acquired by Novartis).11 Oritavancin was initially approved by the FDA in 2014 and formulated to combat susceptible gram-positive bacteria that cause skin and skin structure infections. It boasts the option of single-dose administration and has been proven as non-inferior to a full course of vancomycin therapy.9,8,10
On March 12, 2021 the FDA approved Kimyrsa, a complete course of therapy in a single, 1 hour 1200 mg infusion.16 Orbactiv, the other FDA approved oritavancin product, is administered over a 3 hour infusion and contains a lower dose of 400 mg. Marketed by Melinta Therapeutics, Kimyrsa offers effective and time-efficient treatment for skin and skin structure infections.15
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Structure
Structure for Oritavancin (DB04911)
- Weight
- Average: 1793.101
Monoisotopic: 1790.564106447 - Chemical Formula
- C86H97Cl3N10O26
- Synonyms
- Chlorobiphenyl-chloroeremomycin
- Oritavancin
- External IDs
- LY 333328
- LY-333328
- LY333328
Pharmacology
- Indication
Oritavancin is indicated for the treatment of adult patients with acute bacterial skin and skin structure (including subcutaneous) infection. It is used for confirmed/suspected infections with designated and susceptible gram-positive organisms.10 There are two preparations of oritavancin; the 400 mg dose that is administered over 3 hours, and the 1200 mg dose administered over 1 hour. Both are indicated for susceptible gram-positive skin and skin structure infections in adults.10,15
As antimicrobial susceptibility patterns are geographically distinct, local antibiograms should be consulted to ensure adequate coverage of relevant pathogens prior to use.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Treatment of Skin and skin-structure infections •••••••••••• ••••• •••••••••• ••••••• •••••••••••• ••• •••••••• Treatment of Skin and skin-structure infections •••••••••••• ••••• •••••••••• ••••••• •••••••••••• ••• •••••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Oritavancin interferes with bacterial cell wall synthesis and integrity, treating susceptible skin and subcutaneous tissue infections with gram-positive bacteria.3,10 This drug is known to artifically increase INR and aPTT, interfering with coagulation testing. Cases of infusion reactions have also been reported.10
- Mechanism of action
The cell wall is vital for the survival and replication of bacteria, making it a primary target for antibiotic therapy.4 Oritavancin works against susceptible gram-positive organisms via three separate mechanisms. Firstly, it binds to the stem peptide of peptidoglycan precursors, inhibiting transglycosylation (polymerization). This process normally occurs during cell wall synthesis. Secondly, oritavancin inhibits crosslinking during bacterial cell wall biosynthesis via binding to cell wall pentaglycyl peptide bridging segments. Finally, this drug also acts by disrupting the bacterial cell membrane, interfering with its integrity, which eventually leads to cell death by various mechanisms.5,6,10
Target Actions Organism APeptidoglycan precursors binderABacterial cell wall peptide bridging segments inhibitorStaphylococcus aureus APentaglycyl bridging segment disruptorStaphylococcus aureus - Absorption
Pharmacokinetic analysis of oritavancin revealed a Cmax of 138 and μg/mL and an AUC0-∞ of 2800 μg•h/mL.10 The AUC0-t in a study of healthy volunteers after an 800 mg dose 1,1111 μg•h/mL.1 was also be Another pharmacokinetic study reported a Cmax of 4.7-7.6 micrograms/mL, generally achieved within 24 hours of administration.2
- Volume of distribution
The volume of distribution of oritavancin is estimated at 87.6 L, suggesting extensive tissue distribution.10
- Protein binding
Oritavancin is about 85% bound to plasma proteins.10
- Metabolism
In vitro studies on human hepatocytes suggest that oritavancin is not metabolized, and is excreted unchanged.7,10
- Route of elimination
Oritavancin is excreted as unchanged drug in both the urine and feces. Less than 5% has been recovered in the urine, and 1% has been recovered in the feces.2,10
- Half-life
The average terminal half-life of oritavancin is about 245 hours.10 A pharmacokinetic study revealed a terminal half-life ranging from 135.8-273.8 hours.2
- Clearance
The clearance of oritavancin is approximately 0.445 L/h.10 One study revealed a renal clearance of 0.457 mL/min.2
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
The LD50 of oritavancin in rats is >500m mg/kg.13 Prescribing information indicates no experience with overdose during the clinical program for oritavancin, however, an overdose is likely to result in an increased risk of adverse effects, such as headache, nausea vomiting, and diarrhea. This drug is not dialyzable, and in the case of an overdose, supportive measures should be undertaken.10
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbemaciclib The metabolism of Abemaciclib can be increased when combined with Oritavancin. Abrocitinib The metabolism of Abrocitinib can be decreased when combined with Oritavancin. Acalabrutinib The metabolism of Acalabrutinib can be increased when combined with Oritavancin. Acebutolol The metabolism of Acebutolol can be decreased when combined with Oritavancin. Acenocoumarol The risk or severity of bleeding can be increased when Oritavancin is combined with Acenocoumarol. - Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Oritavancin diphosphate VL1P93MKZN 192564-14-0 PWTROOMOPLCZHB-BHYQHFGMSA-N - International/Other Brands
- Kimyrsa (Melinta Therapeutics, LLC)
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Kimyrsa Injection, powder, lyophilized, for solution 1200 mg/40mL Intravenous Melinta Therapeutics, LLC 2021-03-23 Not applicable US 
Orbactiv Injection, powder, lyophilized, for solution 400 mg/1 Intravenous The Medicines Company 2014-09-01 2021-06-30 US Orbactiv Injection, powder, for solution 400 mg Intravenous Menarini International Operations Luxembourg S.A. 2020-12-22 Not applicable EU 
Orbactiv Injection, powder, lyophilized, for solution 400 mg/1 Intravenous Melinta Therapeutics, LLC 2014-09-01 Not applicable US Orbactiv Injection, powder, lyophilized, for solution 400 mg/1 Intravenous The Medicines Company 2014-09-01 2014-08-12 US
Categories
- ATC Codes
- J01XA05 — Oritavancin
- Drug Categories
- Amino Acids, Peptides, and Proteins
- Anti-Bacterial Agents
- Anti-Infective Agents
- Antibacterials for Systemic Use
- Antiinfectives for Systemic Use
- Carbohydrates
- Cytochrome P-450 CYP2C19 Inhibitors
- Cytochrome P-450 CYP2C19 Inhibitors (weak)
- Cytochrome P-450 CYP2C9 Inhibitors
- Cytochrome P-450 CYP2C9 Inhibitors (weak)
- Cytochrome P-450 CYP2D6 Inhibitors
- Cytochrome P-450 CYP2D6 Inhibitors (weak)
- Cytochrome P-450 CYP3A Inducers
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 CYP3A4 Inducers
- Cytochrome P-450 CYP3A4 Inducers (weak)
- Cytochrome P-450 CYP3A4 Inhibitors
- Cytochrome P-450 CYP3A4 Inhibitors (weak)
- Cytochrome P-450 Enzyme Inducers
- Cytochrome P-450 Enzyme Inhibitors
- Glycoconjugates
- Glycopeptide Antibacterials
- Glycopeptides
- Lipids
- Lipoglycopeptide Antibacterial
- Lipopeptides
- Peptides
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as oligopeptides. These are organic compounds containing a sequence of between three and ten alpha-amino acids joined by peptide bonds.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Carboxylic acids and derivatives
- Sub Class
- Amino acids, peptides, and analogues
- Direct Parent
- Oligopeptides
- Alternative Parents
- Cyclic peptides / Aminoglycosides / Phenolic glycosides / Leucine and derivatives / Chlorinated biphenyls / N-acyl-alpha amino acids and derivatives / Alpha amino acid amides / Diarylethers / Disaccharides / O-glycosyl compounds show 29 more
- Substituents
- 1,2-aminoalcohol / 1-hydroxy-2-unsubstituted benzenoid / 1-hydroxy-4-unsubstituted benzenoid / Acetal / Alcohol / Alpha-amino acid amide / Alpha-amino acid or derivatives / Alpha-oligopeptide / Amine / Amino acid show 55 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- disaccharide derivative, glycopeptide (CHEBI:82699)
- Affected organisms
- Gram-positive Bacteria
- Streptococcus pyogenes
- Streptococcus pneumoniae
- Staphylococcus aureus
- Enterococcus faecalis
Chemical Identifiers
- UNII
- PUG62FRZ2E
- CAS number
- 171099-57-3
- InChI Key
- VHFGEBVPHAGQPI-LXKZPTCJSA-N
- InChI
- InChI=1S/C86H97Cl3N10O26/c1-35(2)22-51(92-7)77(110)98-67-69(105)42-15-20-55(49(88)24-42)120-57-26-44-27-58(73(57)125-84-74(71(107)70(106)59(34-100)122-84)124-62-32-86(6,76(109)37(4)119-62)93-33-38-8-10-39(11-9-38)40-12-17-45(87)18-13-40)121-56-21-16-43(25-50(56)89)72(123-61-31-85(5,91)75(108)36(3)118-61)68-82(115)97-66(83(116)117)48-28-46(101)29-54(103)63(48)47-23-41(14-19-53(47)102)64(79(112)99-68)96-80(113)65(44)95-78(111)52(30-60(90)104)94-81(67)114/h8-21,23-29,35-37,51-52,59,61-62,64-72,74-76,84,92-93,100-103,105-109H,22,30-34,91H2,1-7H3,(H2,90,104)(H,94,114)(H,95,111)(H,96,113)(H,97,115)(H,98,110)(H,99,112)(H,116,117)/t36-,37-,51+,52-,59+,61-,62-,64+,65+,66-,67+,68-,69+,70+,71-,72+,74+,75-,76-,84-,85-,86-/m0/s1
- IUPAC Name
- (1S,2R,18R,19R,22S,25R,28R,40S)-2-{[(2R,4S,5R,6S)-4-amino-5-hydroxy-4,6-dimethyloxan-2-yl]oxy}-22-(carbamoylmethyl)-5,47-dichloro-48-{[(2S,3R,4S,5S,6R)-3-{[(2S,4S,5R,6S)-4-[({4'-chloro-[1,1'-biphenyl]-4-yl}methyl)amino]-5-hydroxy-4,6-dimethyloxan-2-yl]oxy}-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-18,32,35,37-tetrahydroxy-19-[(2R)-4-methyl-2-(methylamino)pentanamido]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentaazaoctacyclo[26.14.2.2^{3,6}.2^{14,17}.1^{8,12}.1^{29,33}.0^{10,25}.0^{34,39}]pentaconta-3,5,8,10,12(48),14,16,29(45),30,32,34,36,38,46,49-pentadecaene-40-carboxylic acid
- SMILES
- CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)C2=CC=C(OC3=C(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@H]4C[C@](C)(NCC5=CC=C(C=C5)C5=CC=C(Cl)C=C5)[C@@H](O)[C@H](C)O4)C4=CC(=C3)[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N[C@@H]1C3=CC(=C(O)C=C3)C3=C(O)C=C(O)C=C3[C@H](NC(=O)[C@@H](NC1=O)[C@H](O[C@H]1C[C@](C)(N)[C@@H](O)[C@H](C)O1)C1=CC(Cl)=C(O4)C=C1)C(O)=O)C(Cl)=C2
References
- Synthesis Reference
Adel Rafai Far, Gopal Krishna, Min Ding, Sanjay R, Chemburkar Carl M, Knable James, J. PETZEL, Julie J Pruyne, Douglas M. Reamer.2015. High purity oritavancin and method of producing same.Patent WO2016011245A1
- General References
- Fetterly GJ, Ong CM, Bhavnani SM, Loutit JS, Porter SB, Morello LG, Ambrose PG, Nicolau DP: Pharmacokinetics of oritavancin in plasma and skin blister fluid following administration of a 200-milligram dose for 3 days or a single 800-milligram dose. Antimicrob Agents Chemother. 2005 Jan;49(1):148-52. [Article]
- Bhavnani SM, Owen JS, Loutit JS, Porter SB, Ambrose PG: Pharmacokinetics, safety, and tolerability of ascending single intravenous doses of oritavancin administered to healthy human subjects. Diagn Microbiol Infect Dis. 2004 Oct;50(2):95-102. [Article]
- Kmeid J, Kanafani ZA: Oritavancin for the treatment of acute bacterial skin and skin structure infections: an evidence-based review. Core Evid. 2015 Feb 11;10:39-47. doi: 10.2147/CE.S51284. eCollection 2015. [Article]
- Schuerholz T, Domming S, Hornef M, Dupont A, Kowalski I, Kaconis Y, Heinbockel L, Andra J, Garidel P, Gutsmann T, David S, Sanchez-Gomez S, Martinez de Tejada G, Brandenburg K: Bacterial cell wall compounds as promising targets of antimicrobial agents II. Immunological and clinical aspects. Curr Drug Targets. 2012 Aug;13(9):1131-7. doi: 10.2174/138945012802002438. [Article]
- Kim SJ, Cegelski L, Stueber D, Singh M, Dietrich E, Tanaka KS, Parr TR Jr, Far AR, Schaefer J: Oritavancin exhibits dual mode of action to inhibit cell-wall biosynthesis in Staphylococcus aureus. J Mol Biol. 2008 Mar 14;377(1):281-93. doi: 10.1016/j.jmb.2008.01.031. Epub 2008 Jan 17. [Article]
- Zhanel GG, Schweizer F, Karlowsky JA: Oritavancin: mechanism of action. Clin Infect Dis. 2012 Apr;54 Suppl 3:S214-9. doi: 10.1093/cid/cir920. [Article]
- Cada DJ, Baker DE: Oritavancin diphosphate. Hosp Pharm. 2014 Dec;49(11):1049-60. doi: 10.1310/hjp4911-1049. [Article]
- Corey GR, Kabler H, Mehra P, Gupta S, Overcash JS, Porwal A, Giordano P, Lucasti C, Perez A, Good S, Jiang H, Moeck G, O'Riordan W: Single-dose oritavancin in the treatment of acute bacterial skin infections. N Engl J Med. 2014 Jun 5;370(23):2180-90. doi: 10.1056/NEJMoa1310422. [Article]
- Rosenthal S, Decano AG, Bandali A, Lai D, Malat GE, Bias TE: Oritavancin (Orbactiv): A New-Generation Lipoglycopeptide for the Treatment Of Acute Bacterial Skin and Skin Structure Infections. P T. 2018 Mar;43(3):143-179. [Article]
- FDA Approved Drug Products: Orbactiv (oritavancin) for intravenous injection [Link]
- Novartis successfully completes acquisition of The Medicines Company, adding a potentially first-in-class, investigational cholesterol-lowering therapy inclisiran [Link]
- DailyMed: Orbactiv (oritavancin) powder for injection [Link]
- Mckesson: Oritavancin diphosphate MSDS [Link]
- Orbactiv website [Link]
- Press release: Melinta therapeutics announces FDA approval of KIMYRSA™ (oritavancin) for the treatment of adult patients with acute bacterial skin and skin structure infections [Link]
- FDA Approved Drug Products: KIMYRSA (oritavancin) for intravenous injection [Link]
- External Links
- KEGG Compound
- C12034
- PubChem Compound
- 16136912
- PubChem Substance
- 175426900
- ChemSpider
- 17286443
- 1547611
- ChEBI
- 82699
- ChEMBL
- CHEMBL1688530
- Wikipedia
- Oritavancin
- FDA label
- Download (527 KB)
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count 4 Completed Other Bacterial skin infections 1 4 Completed Treatment Acute Bacterial Skin and Skin Structure Infection (ABSSSI) 1 4 Enrolling by Invitation Treatment Bone and Joint Infections / Endovascular Infection / Gastrointestinal Tract Infections / Genitourinary tract infection / Pulmonary Infections / Skin and Soft Tissue Infections (SSTIs) 1 4 Not Yet Recruiting Treatment Acute Osteomyelitis / Bacteremia / Septic Arthritis / Soft Tissues Infections / Substance Use Disorders (SUD) 1 4 Withdrawn Treatment Bacteremia caused by Staphylococcus Aureus / Endocarditis caused by staphylococcus aureus 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, powder, lyophilized, for solution Intravenous 1200 mg/40mL Injection, powder, lyophilized, for solution Intravenous 400 mg/1 Injection, powder, for solution Intravenous 1200 mg Injection, powder, for solution Intravenous 400 MG - Prices
- Not Available
- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region US8420592 No 2013-04-16 2029-08-29 US US5840684 No 1998-11-24 2016-11-24 US US5998581 No 1999-12-07 2017-11-12 US US9649352 No 2017-05-16 2035-07-16 US US9682061 No 2017-06-20 2030-04-26 US
Properties
- State
- Solid
- Experimental Properties
Property Value Source boiling point (°C) 810.3 http://www.demechem.com/English/productshow.asp?id=49 water solubility 10 mg/mL https://www.sigmaaldrich.com/catalog/product/sigma/sml1586?lang=fr®ion=CA logP 4.1 PMID: 18375379 pKa 2.93±0.7 https://www.chemicalbook.com/ChemicalProductProperty_EN_CB92451283.htm - Predicted Properties
Property Value Source Water Solubility 0.0588 mg/mL ALOGPS logP 1.92 ALOGPS logP 0.2 Chemaxon logS -4.5 ALOGPS pKa (Strongest Acidic) 2.98 Chemaxon pKa (Strongest Basic) 9.96 Chemaxon Physiological Charge 2 Chemaxon Hydrogen Acceptor Count 27 Chemaxon Hydrogen Donor Count 20 Chemaxon Polar Surface Area 560.98 Å2 Chemaxon Rotatable Bond Count 19 Chemaxon Refractivity 441.59 m3·mol-1 Chemaxon Polarizability 178.55 Å3 Chemaxon Number of Rings 13 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption - 0.6087 Blood Brain Barrier - 0.9905 Caco-2 permeable - 0.7039 P-glycoprotein substrate Substrate 0.9233 P-glycoprotein inhibitor I Non-inhibitor 0.8502 P-glycoprotein inhibitor II Non-inhibitor 0.9262 Renal organic cation transporter Non-inhibitor 0.9503 CYP450 2C9 substrate Non-substrate 0.8721 CYP450 2D6 substrate Non-substrate 0.8153 CYP450 3A4 substrate Substrate 0.6616 CYP450 1A2 substrate Non-inhibitor 0.881 CYP450 2C9 inhibitor Non-inhibitor 0.8283 CYP450 2D6 inhibitor Non-inhibitor 0.8541 CYP450 2C19 inhibitor Non-inhibitor 0.8122 CYP450 3A4 inhibitor Non-inhibitor 0.6912 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.7622 Ames test Non AMES toxic 0.6154 Carcinogenicity Non-carcinogens 0.8151 Biodegradation Not ready biodegradable 1.0 Rat acute toxicity 2.6222 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9983 hERG inhibition (predictor II) Non-inhibitor 0.5464
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
1. Peptidoglycan precursors
Yes
Binder
References
- Munch D, Engels I, Muller A, Reder-Christ K, Falkenstein-Paul H, Bierbaum G, Grein F, Bendas G, Sahl HG, Schneider T: Structural variations of the cell wall precursor lipid II and their influence on binding and activity of the lipoglycopeptide antibiotic oritavancin. Antimicrob Agents Chemother. 2015 Feb;59(2):772-81. doi: 10.1128/AAC.02663-14. Epub 2014 Nov 17. [Article]
- Kim SJ, Cegelski L, Stueber D, Singh M, Dietrich E, Tanaka KS, Parr TR Jr, Far AR, Schaefer J: Oritavancin exhibits dual mode of action to inhibit cell-wall biosynthesis in Staphylococcus aureus. J Mol Biol. 2008 Mar 14;377(1):281-93. doi: 10.1016/j.jmb.2008.01.031. Epub 2008 Jan 17. [Article]
- FDA Approved Drug Products: Orbactiv (oritavancin) for intravenous injection [Link]
2. Bacterial cell wall peptide bridging segments
Yes
Inhibitor
References
- Kim SJ, Cegelski L, Stueber D, Singh M, Dietrich E, Tanaka KS, Parr TR Jr, Far AR, Schaefer J: Oritavancin exhibits dual mode of action to inhibit cell-wall biosynthesis in Staphylococcus aureus. J Mol Biol. 2008 Mar 14;377(1):281-93. doi: 10.1016/j.jmb.2008.01.031. Epub 2008 Jan 17. [Article]
- Zhanel GG, Schweizer F, Karlowsky JA: Oritavancin: mechanism of action. Clin Infect Dis. 2012 Apr;54 Suppl 3:S214-9. doi: 10.1093/cid/cir920. [Article]
- FDA Approved Drug Products: Orbactiv (oritavancin) for intravenous injection [Link]
3. Pentaglycyl bridging segment
Yes
Disruptor
References
- Kim SJ, Cegelski L, Stueber D, Singh M, Dietrich E, Tanaka KS, Parr TR Jr, Far AR, Schaefer J: Oritavancin exhibits dual mode of action to inhibit cell-wall biosynthesis in Staphylococcus aureus. J Mol Biol. 2008 Mar 14;377(1):281-93. doi: 10.1016/j.jmb.2008.01.031. Epub 2008 Jan 17. [Article]
- Zhanel GG, Schweizer F, Karlowsky JA: Oritavancin: mechanism of action. Clin Infect Dis. 2012 Apr;54 Suppl 3:S214-9. doi: 10.1093/cid/cir920. [Article]
- FDA Approved Drug Products: Orbactiv (oritavancin) for intravenous injection [Link]
Enzymes
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- InhibitorInducer
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
References
- FDA Approved Drug Products: Orbactiv (oritavancin) for intravenous injection [Link]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- InhibitorInducer
- Curator comments
- While CYP2D6 is generally not an inducible enzyme, the FDA Label states that oritavancin may induce CYP2D6 based on general activity of oritavancin on other CYP enzymes. There is not enough evidence that such modulation of the enzyme will lead to clinically significant drug-drug interactions.
- General Function
- Steroid hydroxylase activity
- Specific Function
- Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
- Gene Name
- CYP2D6
- Uniprot ID
- P10635
- Uniprot Name
- Cytochrome P450 2D6
- Molecular Weight
- 55768.94 Da
References
- Cada DJ, Baker DE: Oritavancin diphosphate. Hosp Pharm. 2014 Dec;49(11):1049-60. doi: 10.1310/hjp4911-1049. [Article]
- Brade KD, Rybak JM, Rybak MJ: Oritavancin: A New Lipoglycopeptide Antibiotic in the Treatment of Gram-Positive Infections. Infect Dis Ther. 2016 Mar;5(1):1-15. doi: 10.1007/s40121-016-0103-4. Epub 2016 Feb 1. [Article]
- FDA Approved Drug Products: Orbactiv (oritavancin) for intravenous injection [Link]
- EMA Assessment Report: Orbactiv [Link]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Steroid hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP2C9
- Uniprot ID
- P11712
- Uniprot Name
- Cytochrome P450 2C9
- Molecular Weight
- 55627.365 Da
References
- Rosenthal S, Decano AG, Bandali A, Lai D, Malat GE, Bias TE: Oritavancin (Orbactiv): A New-Generation Lipoglycopeptide for the Treatment Of Acute Bacterial Skin and Skin Structure Infections. P T. 2018 Mar;43(3):143-179. [Article]
- Cada DJ, Baker DE: Oritavancin diphosphate. Hosp Pharm. 2014 Dec;49(11):1049-60. doi: 10.1310/hjp4911-1049. [Article]
- Oritavancin FDA label [File]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Steroid hydroxylase activity
- Specific Function
- Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
- Gene Name
- CYP2C19
- Uniprot ID
- P33261
- Uniprot Name
- Cytochrome P450 2C19
- Molecular Weight
- 55930.545 Da
References
- Brade KD, Rybak JM, Rybak MJ: Oritavancin: A New Lipoglycopeptide Antibiotic in the Treatment of Gram-Positive Infections. Infect Dis Ther. 2016 Mar;5(1):1-15. doi: 10.1007/s40121-016-0103-4. Epub 2016 Feb 1. [Article]
- Cada DJ, Baker DE: Oritavancin diphosphate. Hosp Pharm. 2014 Dec;49(11):1049-60. doi: 10.1310/hjp4911-1049. [Article]
Carriers
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Binder
- General Function
- Toxic substance binding
- Specific Function
- Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
- Gene Name
- ALB
- Uniprot ID
- P02768
- Uniprot Name
- Serum albumin
- Molecular Weight
- 69365.94 Da
References
- McKay GA, Beaulieu S, Sarmiento I, Arhin FF, Parr TR Jr, Moeck G: Impact of human serum albumin on oritavancin in vitro activity against enterococci. Antimicrob Agents Chemother. 2009 Jun;53(6):2687-9. doi: 10.1128/AAC.00197-09. Epub 2009 Apr 6. [Article]
Drug created at October 21, 2007 22:23 / Updated at February 02, 2024 22:53